Eric Venker, President & Immunovant Chief Executive Officer, on April 20, 2026, sold 200,000 shares in Roivant Sciences (ROIV) for $5,918,000. Following the Form 4 filing with the SEC, Venker has control over a total of 1,647,546 common shares of the company, with 1,647,546 shares held directly.
SEC Filing:
Kamal Seyed Ghaffarian, 10% Owner, Director, on April 20, 2026, sold 141,909 shares in Intuitive Machines (LUNR) for $3,995,956. Following the Form 4 filing with the SEC, Ghaffarian has control over a total of 3,640,860 Class A common shares of the company, with 146,092 shares held directly and 3,494,768 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1844452/000121390026046720/xslF345X05/ownership.xml
Oluyemi Okupe, Chief Financial Officer, on April 20, 2026, sold 19,645 shares in Hims & Hers Health (HIMS) for $588,615. Following the Form 4 filing with the SEC, Okupe has control over a total of 270,807 Class A common shares of the company, with 262,954 shares held directly and 7,853 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1773751/000190705626000016/xslF345X05/wk-form4_1776893044.xml
Soleil Boughton, Chief Legal Officer, on April 20, 2026, sold 9,463 shares in Hims & Hers Health (HIMS) for $283,890. Following the Form 4 filing with the SEC, Boughton has control over a total of 299,368 Class A common shares of the company, with 299,368 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1773751/000183781726000009/xslF345X05/wk-form4_1776893050.xml